An Established Th2-Oriented Response to an Alum-Adjuvanted SARS-CoV-2 Subunit Vaccine Is Not Reversible by Sequential Immunization with Nucleic Acid-Adjuvanted Th1-Oriented Subunit Vaccines

A recently reported parallel preclinical study between a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine and an inactivated SARS-CoV-2 vaccine adjuvanted with alum showed pulmonary immunopathology typical of eosinophil accumulation in a mouse pneumonia model for the latter,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Han Cao, Shengran Yang, Yunfei Wang, Ning Luan, Xingxiao Yin, Kangyang Lin, Cunbao Liu
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	SARS-CoV-2 subunit vaccine Th1/Th2 orientation alum adjuvant nucleic acid adjuvant prime-boost homogenous boost immunization Medicine R
Acceso en línea:	https://doaj.org/article/5ceb0ef61a884eefadfdc00ad3a3b079
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5ceb0ef61a884eefadfdc00ad3a3b079
record_format	dspace
spelling	oai:doaj.org-article:5ceb0ef61a884eefadfdc00ad3a3b0792021-11-25T19:10:39ZAn Established Th2-Oriented Response to an Alum-Adjuvanted SARS-CoV-2 Subunit Vaccine Is Not Reversible by Sequential Immunization with Nucleic Acid-Adjuvanted Th1-Oriented Subunit Vaccines10.3390/vaccines91112612076-393Xhttps://doaj.org/article/5ceb0ef61a884eefadfdc00ad3a3b0792021-11-01T00:00:00Zhttps://www.mdpi.com/2076-393X/9/11/1261https://doaj.org/toc/2076-393XA recently reported parallel preclinical study between a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine and an inactivated SARS-CoV-2 vaccine adjuvanted with alum showed pulmonary immunopathology typical of eosinophil accumulation in a mouse pneumonia model for the latter, which implied a potential role of cellular immunity in the difference in the protection rate between these two forms of vaccines. For those who have been vaccinated with alum-adjuvanted subunit or inactivated SARS-CoV-2 vaccines, whether the Th2 responses that have been established and the absence of induced cellular immunity could be changed is an open question. Using two heterologous boosts with Th1-oriented CpG ODN-adjuvanted S1-based SARS-CoV-2 subunit vaccines for mice that were primed with two doses of Th2-oriented alum-adjuvanted S1-based SARS-CoV-2 subunit vaccines, we demonstrated that established Th2 orientation could not be reversed to Th1 orientation and that no cellular immunity was induced, which should have been induced if the boosting vaccines were used as the prime vaccines. These results remind us that if widely administered alum-adjuvanted SARS-CoV-2 vaccines cannot overcome the challenge of coronavirus disease 2019 (COVID-19) and that if cellular immunity is important for the efficacy of SARS-CoV-2 vaccines in the future, the choice of more powerful heterologous boosting vaccine forms that can induce cellular immunity should be considered very carefully before application.Han CaoShengran YangYunfei WangNing LuanXingxiao YinKangyang LinCunbao LiuMDPI AGarticleSARS-CoV-2 subunit vaccineTh1/Th2 orientationalum adjuvantnucleic acid adjuvantprime-boosthomogenous boost immunizationMedicineRENVaccines, Vol 9, Iss 1261, p 1261 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	SARS-CoV-2 subunit vaccine Th1/Th2 orientation alum adjuvant nucleic acid adjuvant prime-boost homogenous boost immunization Medicine R
spellingShingle	SARS-CoV-2 subunit vaccine Th1/Th2 orientation alum adjuvant nucleic acid adjuvant prime-boost homogenous boost immunization Medicine R Han Cao Shengran Yang Yunfei Wang Ning Luan Xingxiao Yin Kangyang Lin Cunbao Liu An Established Th2-Oriented Response to an Alum-Adjuvanted SARS-CoV-2 Subunit Vaccine Is Not Reversible by Sequential Immunization with Nucleic Acid-Adjuvanted Th1-Oriented Subunit Vaccines
description	A recently reported parallel preclinical study between a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine and an inactivated SARS-CoV-2 vaccine adjuvanted with alum showed pulmonary immunopathology typical of eosinophil accumulation in a mouse pneumonia model for the latter, which implied a potential role of cellular immunity in the difference in the protection rate between these two forms of vaccines. For those who have been vaccinated with alum-adjuvanted subunit or inactivated SARS-CoV-2 vaccines, whether the Th2 responses that have been established and the absence of induced cellular immunity could be changed is an open question. Using two heterologous boosts with Th1-oriented CpG ODN-adjuvanted S1-based SARS-CoV-2 subunit vaccines for mice that were primed with two doses of Th2-oriented alum-adjuvanted S1-based SARS-CoV-2 subunit vaccines, we demonstrated that established Th2 orientation could not be reversed to Th1 orientation and that no cellular immunity was induced, which should have been induced if the boosting vaccines were used as the prime vaccines. These results remind us that if widely administered alum-adjuvanted SARS-CoV-2 vaccines cannot overcome the challenge of coronavirus disease 2019 (COVID-19) and that if cellular immunity is important for the efficacy of SARS-CoV-2 vaccines in the future, the choice of more powerful heterologous boosting vaccine forms that can induce cellular immunity should be considered very carefully before application.
format	article
author	Han Cao Shengran Yang Yunfei Wang Ning Luan Xingxiao Yin Kangyang Lin Cunbao Liu
author_facet	Han Cao Shengran Yang Yunfei Wang Ning Luan Xingxiao Yin Kangyang Lin Cunbao Liu
author_sort	Han Cao
title	An Established Th2-Oriented Response to an Alum-Adjuvanted SARS-CoV-2 Subunit Vaccine Is Not Reversible by Sequential Immunization with Nucleic Acid-Adjuvanted Th1-Oriented Subunit Vaccines
title_short	An Established Th2-Oriented Response to an Alum-Adjuvanted SARS-CoV-2 Subunit Vaccine Is Not Reversible by Sequential Immunization with Nucleic Acid-Adjuvanted Th1-Oriented Subunit Vaccines
title_full	An Established Th2-Oriented Response to an Alum-Adjuvanted SARS-CoV-2 Subunit Vaccine Is Not Reversible by Sequential Immunization with Nucleic Acid-Adjuvanted Th1-Oriented Subunit Vaccines
title_fullStr	An Established Th2-Oriented Response to an Alum-Adjuvanted SARS-CoV-2 Subunit Vaccine Is Not Reversible by Sequential Immunization with Nucleic Acid-Adjuvanted Th1-Oriented Subunit Vaccines
title_full_unstemmed	An Established Th2-Oriented Response to an Alum-Adjuvanted SARS-CoV-2 Subunit Vaccine Is Not Reversible by Sequential Immunization with Nucleic Acid-Adjuvanted Th1-Oriented Subunit Vaccines
title_sort	established th2-oriented response to an alum-adjuvanted sars-cov-2 subunit vaccine is not reversible by sequential immunization with nucleic acid-adjuvanted th1-oriented subunit vaccines
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/5ceb0ef61a884eefadfdc00ad3a3b079
work_keys_str_mv	AT hancao anestablishedth2orientedresponsetoanalumadjuvantedsarscov2subunitvaccineisnotreversiblebysequentialimmunizationwithnucleicacidadjuvantedth1orientedsubunitvaccines AT shengranyang anestablishedth2orientedresponsetoanalumadjuvantedsarscov2subunitvaccineisnotreversiblebysequentialimmunizationwithnucleicacidadjuvantedth1orientedsubunitvaccines AT yunfeiwang anestablishedth2orientedresponsetoanalumadjuvantedsarscov2subunitvaccineisnotreversiblebysequentialimmunizationwithnucleicacidadjuvantedth1orientedsubunitvaccines AT ningluan anestablishedth2orientedresponsetoanalumadjuvantedsarscov2subunitvaccineisnotreversiblebysequentialimmunizationwithnucleicacidadjuvantedth1orientedsubunitvaccines AT xingxiaoyin anestablishedth2orientedresponsetoanalumadjuvantedsarscov2subunitvaccineisnotreversiblebysequentialimmunizationwithnucleicacidadjuvantedth1orientedsubunitvaccines AT kangyanglin anestablishedth2orientedresponsetoanalumadjuvantedsarscov2subunitvaccineisnotreversiblebysequentialimmunizationwithnucleicacidadjuvantedth1orientedsubunitvaccines AT cunbaoliu anestablishedth2orientedresponsetoanalumadjuvantedsarscov2subunitvaccineisnotreversiblebysequentialimmunizationwithnucleicacidadjuvantedth1orientedsubunitvaccines AT hancao establishedth2orientedresponsetoanalumadjuvantedsarscov2subunitvaccineisnotreversiblebysequentialimmunizationwithnucleicacidadjuvantedth1orientedsubunitvaccines AT shengranyang establishedth2orientedresponsetoanalumadjuvantedsarscov2subunitvaccineisnotreversiblebysequentialimmunizationwithnucleicacidadjuvantedth1orientedsubunitvaccines AT yunfeiwang establishedth2orientedresponsetoanalumadjuvantedsarscov2subunitvaccineisnotreversiblebysequentialimmunizationwithnucleicacidadjuvantedth1orientedsubunitvaccines AT ningluan establishedth2orientedresponsetoanalumadjuvantedsarscov2subunitvaccineisnotreversiblebysequentialimmunizationwithnucleicacidadjuvantedth1orientedsubunitvaccines AT xingxiaoyin establishedth2orientedresponsetoanalumadjuvantedsarscov2subunitvaccineisnotreversiblebysequentialimmunizationwithnucleicacidadjuvantedth1orientedsubunitvaccines AT kangyanglin establishedth2orientedresponsetoanalumadjuvantedsarscov2subunitvaccineisnotreversiblebysequentialimmunizationwithnucleicacidadjuvantedth1orientedsubunitvaccines AT cunbaoliu establishedth2orientedresponsetoanalumadjuvantedsarscov2subunitvaccineisnotreversiblebysequentialimmunizationwithnucleicacidadjuvantedth1orientedsubunitvaccines
_version_	1718410218039148544

An Established Th2-Oriented Response to an Alum-Adjuvanted SARS-CoV-2 Subunit Vaccine Is Not Reversible by Sequential Immunization with Nucleic Acid-Adjuvanted Th1-Oriented Subunit Vaccines

Ejemplares similares